TW586934B
(en)
*
|
1997-05-19 |
2004-05-11 |
Sumitomo Pharma |
Immunopotentiating composition
|
US7241730B2
(en)
|
1998-08-27 |
2007-07-10 |
Universitat Zurich |
Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
|
US20020081732A1
(en)
*
|
2000-10-18 |
2002-06-27 |
Bowlin Gary L. |
Electroprocessing in drug delivery and cell encapsulation
|
US7615373B2
(en)
*
|
1999-02-25 |
2009-11-10 |
Virginia Commonwealth University Intellectual Property Foundation |
Electroprocessed collagen and tissue engineering
|
US20040018226A1
(en)
*
|
1999-02-25 |
2004-01-29 |
Wnek Gary E. |
Electroprocessing of materials useful in drug delivery and cell encapsulation
|
US6083933A
(en)
*
|
1999-04-19 |
2000-07-04 |
Stellar International Inc. |
Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
|
WO2001066164A1
(en)
*
|
1999-04-22 |
2001-09-13 |
Eidgenossisch Technische Hochschule Zurich |
Modified protein matrices
|
WO2000064481A1
(en)
*
|
1999-04-22 |
2000-11-02 |
Eidgenössische Technische Hochschule (ETH) |
Controlled release of growth factors from heparin containing matrices
|
EP1315756A2
(de)
*
|
2000-09-01 |
2003-06-04 |
Virginia Commonwealth University Intellectual Property Foundation |
Elektroplattierte fibrin-basierte träger und gewebe
|
CA2325842C
(en)
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
US7182944B2
(en)
*
|
2001-04-25 |
2007-02-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of increasing distribution of nucleic acids
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
EP1443944A1
(de)
*
|
2001-11-12 |
2004-08-11 |
Johannes Reinmüller |
Pharmazeutische anwendungen von hyaluronsäure-präparaten
|
WO2003066083A1
(fr)
*
|
2002-02-04 |
2003-08-14 |
Sumitomo Pharmaceuticals Company, Limited |
Preparations pour le traitement de fracture osseuse de deperdition osseuse ou d'augmentation la densite osseuse
|
CA2476556A1
(en)
|
2002-02-13 |
2003-08-21 |
Duke University |
Modulation of immune response by non-peptide binding stress response polypeptides
|
EP1558282A4
(de)
|
2002-10-01 |
2006-04-19 |
Chiron Corp |
Zusammensetzungen gegen krebs und infektionskrankheiten und anwendungsverfahren dafür
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20040161476A1
(en)
|
2003-02-19 |
2004-08-19 |
Hahn Sungtack Samuel |
Cystitis treatment with high dose chondroitin sulfate
|
ATE551339T1
(de)
|
2003-11-05 |
2012-04-15 |
Sarcode Bioscience Inc |
Modulatoren der zellulären adhäsion
|
FR2862878B1
(fr)
*
|
2003-11-27 |
2006-03-24 |
Sofradim Production |
Substrat metallique revetu d'une composition de collagene et de polysaccharides, procede et applications
|
GB0402131D0
(en)
|
2004-01-30 |
2004-03-03 |
Isis Innovation |
Delivery method
|
US20060039949A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Nycz Jeffrey H |
Acetabular cup with controlled release of an osteoinductive formulation
|
US20060045902A1
(en)
*
|
2004-09-01 |
2006-03-02 |
Serbousek Jon C |
Polymeric wrap for in vivo delivery of osteoinductive formulations
|
US20060057184A1
(en)
*
|
2004-09-16 |
2006-03-16 |
Nycz Jeffrey H |
Process to treat avascular necrosis (AVN) with osteoinductive materials
|
US8137664B2
(en)
*
|
2005-02-02 |
2012-03-20 |
Sdgi Holdings, Inc. |
Method and kit for repairing a defect in bone
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
CN101189249B
(zh)
|
2005-04-01 |
2013-04-17 |
加利福尼亚大学董事会 |
膦酰基-戊-2-烯-1-基核苷和类似物
|
JP5794721B2
(ja)
|
2005-05-17 |
2015-10-14 |
サーコード バイオサイエンス インコーポレイテッド |
眼障害の治療のための組成物および方法
|
EP1981525B1
(de)
|
2005-12-30 |
2015-01-21 |
Zensun (Shanghai) Science and Technology Limited |
Verlängerte freisetzung von neuregulin für verbesserte herzfunktion
|
EP1993590B1
(de)
*
|
2006-03-01 |
2013-12-25 |
Biogen Idec MA Inc. |
Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
EP2383271B1
(de)
|
2006-03-13 |
2013-07-10 |
Kyorin Pharmaceutical Co., Ltd. |
Aminochinolone als GSK-3-Hemmer
|
BRPI0708879A2
(pt)
*
|
2006-03-13 |
2011-06-14 |
Encysive Pharmaceuticals |
peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
EP2066662B1
(de)
|
2006-09-21 |
2012-12-05 |
Kyorin Pharmaceutical Co., Ltd. |
Serinhydrolasehemmer
|
AU2007310949A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
MX2009006812A
(es)
*
|
2006-12-22 |
2009-07-02 |
Encysive Pharmaceuticals Inc |
Moduladores del receptor c3a y metodos de uso de los mismos.
|
AU2008219622A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
EP2125698B1
(de)
|
2007-03-15 |
2016-08-31 |
Auspex Pharmaceuticals, Inc. |
DEUTERIERTES d9-VENLAFAXINE
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
MX2010000465A
(es)
*
|
2007-07-12 |
2010-08-30 |
Tragara Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
|
US8389514B2
(en)
*
|
2007-09-11 |
2013-03-05 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
CN102344457B
(zh)
|
2007-09-12 |
2015-07-22 |
杏林制药株式会社 |
作为 gsk-3 抑制剂的螺环状氨基喹诺酮
|
EP2209371B1
(de)
*
|
2007-10-19 |
2017-01-04 |
SARcode Bioscience Inc. |
Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
|
WO2009079712A1
(en)
|
2007-12-24 |
2009-07-02 |
The University Of Queensland |
Coating method
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009097660A1
(en)
*
|
2008-02-07 |
2009-08-13 |
The University Of Queensland |
Patch production
|
CA2718123C
(en)
|
2008-03-17 |
2017-08-22 |
Ambit Biosciences Corporation |
Quinazoline derivatives as raf kinase modulators and methods of use thereof
|
US8080562B2
(en)
*
|
2008-04-15 |
2011-12-20 |
Sarcode Bioscience Inc. |
Crystalline pharmaceutical and methods of preparation and use thereof
|
JP2011516607A
(ja)
*
|
2008-04-15 |
2011-05-26 |
サーコード コーポレイション |
胃腸系へのlfa−1アンタゴニストの送達
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
EP2303327A2
(de)
*
|
2008-05-20 |
2011-04-06 |
Cerenis Therapeutics S.A. |
Niacin und nsar für eine kombinationstherapie
|
AU2009250341A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Queensland |
Analyte detection using a needle projection patch
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CN102177172A
(zh)
|
2008-07-02 |
2011-09-07 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
US20110200525A1
(en)
*
|
2008-10-09 |
2011-08-18 |
Patz Jr Edward F |
Vhh antibody fragments for use in the detection and treatment of cancer
|
US8734697B2
(en)
|
2008-12-22 |
2014-05-27 |
The University Of Queensland |
Patch production
|
EP2376524B1
(de)
|
2008-12-31 |
2017-03-15 |
Cypralis Limited |
Derivate von cyclosporin a
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
CN105601619A
(zh)
|
2009-02-27 |
2016-05-25 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
EP2403860B1
(de)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
|
AU2010221990B2
(en)
*
|
2009-03-11 |
2015-06-04 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
WO2010110685A2
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy
|
RU2532515C2
(ru)
|
2009-04-22 |
2014-11-10 |
Аксикин Фармасьютикалз, Инк. |
2,5-дизамещенные арилсульфонамидные антагонисты ccr3
|
CN102459177B
(zh)
|
2009-04-22 |
2015-09-02 |
埃克希金医药品有限公司 |
2,5-二取代的芳基磺酰胺ccr3拮抗剂
|
SG175277A1
(en)
|
2009-04-22 |
2011-11-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide ccr3 antagonists
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
TW201105662A
(en)
|
2009-07-07 |
2011-02-16 |
Pathway Therapeutics Ltd |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
JP5905387B2
(ja)
|
2009-07-08 |
2016-04-20 |
ホープ メディカル エンタープライゼズ,インコーポレイテッド ディービーエー ホープ ファーマシュティカルズHope Medical Enterprises,Inc.Dba Hope Pharmaceuticals |
チオ硫酸ナトリウムを含有する薬学的組成物
|
WO2011009961A1
(en)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
JP2013501068A
(ja)
|
2009-08-05 |
2013-01-10 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
JP2013502429A
(ja)
|
2009-08-19 |
2013-01-24 |
アムビト ビオスシエンセス コルポラチオン |
ビアリール化合物及びその使用方法
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
WO2011050175A1
(en)
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
TW201136942A
(en)
|
2009-12-18 |
2011-11-01 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
|
IN2012DN04858A
(de)
*
|
2009-12-23 |
2015-09-25 |
Map Pharmaceuticals Inc |
|
JP2013516424A
(ja)
|
2009-12-30 |
2013-05-13 |
サイネクシス,インコーポレーテッド |
シクロスポリン類似体
|
WO2011089167A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
US9120815B2
(en)
|
2010-02-05 |
2015-09-01 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
RS59275B1
(sr)
|
2010-02-11 |
2019-10-31 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
|
CA2791964A1
(en)
|
2010-03-02 |
2011-09-09 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
US8741894B2
(en)
|
2010-03-17 |
2014-06-03 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
MX2012013879A
(es)
|
2010-06-01 |
2013-04-03 |
Biotheryx Inc |
Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
|
EP2585063A1
(de)
|
2010-06-01 |
2013-05-01 |
Biotheryx Inc. |
Verfahren zur behandlung von hämatologischen malignomen mit 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridon
|
AU2011265047B2
(en)
|
2010-06-07 |
2014-10-23 |
Novomedix, Llc |
Furanyl compounds and the use thereof
|
US9943673B2
(en)
|
2010-07-14 |
2018-04-17 |
Vaxxas Pty Limited |
Patch applying apparatus
|
CA2805745C
(en)
|
2010-07-19 |
2019-01-15 |
Summa Health System |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
US8703943B2
(en)
|
2010-09-01 |
2014-04-22 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
JP5901634B2
(ja)
|
2010-09-01 |
2016-04-13 |
アムビト ビオスシエンセス コルポラチオン |
キナゾリン化合物及びその使用方法
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
KR20130141469A
(ko)
|
2010-09-01 |
2013-12-26 |
암비트 바이오사이언시즈 코포레이션 |
피라졸릴아미노퀴나졸린의 브롬화수소 염
|
EP2663553B1
(de)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Chinolin- und isochinolinverbindungen zur verwendung als jak-modulatoren
|
EP2611502A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosin-a3-rezeptormodulierende verbindungen und ihre verwendung
|
EP2611812A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
JP2013543512A
(ja)
|
2010-10-11 |
2013-12-05 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
アリールスルホンアミドccr3アンタゴニストの塩
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
BR112013014021A8
(pt)
|
2010-12-06 |
2017-10-03 |
Follica Inc |
Métodos para tratamento de calvície e promoção de crescimento de cabelos
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
MX348152B
(es)
|
2010-12-14 |
2017-06-02 |
Nat Univ Singapore |
Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.
|
UA115767C2
(uk)
|
2011-01-10 |
2017-12-26 |
Інфініті Фармасьютікалз, Інк. |
Способи отримання ізохінолінонів і тверді форми ізохінолінонів
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
TWI542349B
(zh)
|
2011-03-11 |
2016-07-21 |
西建公司 |
利用3-(5-胺基-2-甲基-4-氧基-4h-喹唑啉-3-基)-六氫吡啶-2,6-二酮治療癌症之方法
|
EP2691389A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(alpha-substituierte cycloalkylamino- und) heterocyclylamino-)pyrimidinyl- und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
WO2012135160A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
EP2691388A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
CA2835018C
(en)
|
2011-05-04 |
2020-04-21 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
MX2013015373A
(es)
|
2011-06-23 |
2014-02-11 |
Map Pharmaceuticals Inc |
Nuevos analogos de fluoroergolina.
|
AU2012284091B2
(en)
|
2011-07-19 |
2015-11-12 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013032591A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2755985B1
(de)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
AU2012323782B2
(en)
|
2011-10-12 |
2017-04-06 |
Vaxxas Pty Limited |
Delivery device
|
AU2012322095B2
(en)
|
2011-10-14 |
2017-06-29 |
Ambit Biosciences Corporation |
Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013095707A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
WO2013095708A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
CA2867469A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2852604B1
(de)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
PE20150132A1
(es)
|
2012-05-22 |
2015-02-14 |
Idenix Pharmaceuticals Inc |
Compuestos d-aminoacidos para enfermedad hepatica
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
CN110922393A
(zh)
|
2012-07-25 |
2020-03-27 |
诺华股份有限公司 |
Lfa-1抑制剂及其多晶型物
|
HUE049569T2
(hu)
|
2012-08-09 |
2020-09-28 |
Celgene Corp |
Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése
|
AR094997A1
(es)
|
2012-08-09 |
2015-09-16 |
Celgene Corp |
Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
|
EP2890370B1
(de)
|
2012-08-31 |
2019-10-09 |
The Regents of the University of California |
Mittel zur behandlung von adipositas, diabetes und verwandten erkrankungen
|
BR112015004959A2
(pt)
|
2012-09-07 |
2017-07-04 |
Axikin Pharmaceuticals Inc |
composto isotopicamente enriquecido, composição farmacêutica, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença, distúrbio ou condição mediada por ccr3, relacionada a eosinófilos, relacionada a basófilos, relacionada a mastócitos ou relacionada a mastócitos em um sujeito, método para tratar, prevenir ou amenizar um ou mais sintomas de uma doença inflamatória em um sujeito e método para modular a atividade de ccr3.
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
CA2887578A1
(en)
|
2012-10-08 |
2014-04-17 |
Idenix Pharamaceuticals, Inc. |
2'-chloro nucleoside analogs for hcv infection
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
CN105102000B
(zh)
|
2012-11-01 |
2021-10-22 |
无限药品公司 |
使用pi3激酶亚型调节剂的癌症疗法
|
EP2916830A2
(de)
|
2012-11-08 |
2015-09-16 |
Summa Health System |
Kombinationen aus vitamin c, vitamin k und einem polyphenol zur wundheilung
|
WO2014078427A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
EP2938624A1
(de)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alaninester von sp-nukleosidanalogon
|
WO2014085633A1
(en)
|
2012-11-30 |
2014-06-05 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
SG11201504931SA
(en)
|
2012-12-21 |
2015-07-30 |
Map Pharmaceuticals Inc |
Novel methysergide derivatives
|
EP2943188A1
(de)
|
2013-01-11 |
2015-11-18 |
Mayo Foundation for Medical Education and Research |
Vitamine c und k zur behandlung polyzystischer erkrankungen
|
EP3718557A3
(de)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylat-cyclase-rezeptoragonist sp-333 zur verwendung in der darmreinigung
|
EP2970358B1
(de)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-deoxy-nukleoside zur behandlung von hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
RU2705204C2
(ru)
|
2013-05-30 |
2019-11-06 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ piз-киназы
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
SG11201601341QA
(en)
|
2013-08-30 |
2016-03-30 |
Ambit Biosciences Corp |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TWI657085B
(zh)
|
2013-10-04 |
2019-04-21 |
英菲尼提製藥股份有限公司 |
雜環化合物及其用途
|
MY176976A
(en)
|
2013-10-10 |
2020-08-28 |
Bausch Health Ireland Ltd |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
RU2016125213A
(ru)
|
2013-11-27 |
2017-12-29 |
АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Нуклеотиды для лечения рака печени
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
WO2015183346A2
(en)
|
2014-01-31 |
2015-12-03 |
Washington University |
Imaging and treatment of pathophysiologic conditions by cerenkov radiation
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
JP6701088B2
(ja)
|
2014-03-19 |
2020-05-27 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物
|
PT3119762T
(pt)
|
2014-03-20 |
2021-08-31 |
Capella Therapeutics Inc |
Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
|
CN106661027B
(zh)
|
2014-03-20 |
2019-12-24 |
卡佩拉医疗公司 |
苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
|
US10106549B2
(en)
|
2014-04-09 |
2018-10-23 |
Siteone Therapeutics, Inc. |
10′,11′-modified saxitoxins useful for the treatment of pain
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
BR112016026560A2
(pt)
|
2014-05-12 |
2017-08-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
|
AU2015265607A1
(en)
|
2014-05-28 |
2016-11-17 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
US9974870B2
(en)
|
2014-06-09 |
2018-05-22 |
Washington University |
Compositions and methods for treatment and imaging using nanoparticles
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
CR20170011A
(es)
|
2014-06-19 |
2017-04-04 |
Ariad Pharma Inc |
Compuestos de heteroarilo para la inhibición de cinasa
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
EP3783034A1
(de)
|
2014-07-23 |
2021-02-24 |
Ohio State Innovation Foundation |
Verfahren und zusammensetzungen im zusammenhang mit antikörperfragmenten zur bindung an das tumorassoziierte glycoprotein 72 (tag 72)
|
EP3172222A4
(de)
|
2014-07-24 |
2018-03-21 |
Washington University |
Gegen strahlungsinduzierte moleküle gerichtete zusammensetzungen und verfahren zur verwendung davon
|
BR112017004708A2
(pt)
|
2014-09-12 |
2017-12-05 |
Tobira Therapeutics Inc |
terapia de combinação de cenicriviroc para o tratamento de fibrose
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
EA035145B1
(ru)
|
2014-10-21 |
2020-05-06 |
Ариад Фармасьютикалз, Инк. |
Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]фенил}пиримидин-2,4-диамина
|
EP3209658A1
(de)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoidderivate und verfahren zur verwendung
|
HUE049801T2
(hu)
|
2014-12-23 |
2020-10-28 |
Sma Therapeutics Inc |
3,5-diaminopirazol kináz inhibitorok
|
BR112017015510A2
(pt)
|
2015-01-20 |
2018-01-30 |
Xoc Pharmaceuticals Inc |
composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
|
MX2017009405A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo ergolina y usos de estos.
|
EP4218892A1
(de)
|
2015-02-02 |
2023-08-02 |
Vaxxas Pty Limited |
Mikroprojektionsarrayapplikator
|
US10815264B2
(en)
|
2015-05-27 |
2020-10-27 |
Southern Research Institute |
Nucleotides for the treatment of cancer
|
JP6919099B2
(ja)
|
2015-06-23 |
2021-08-18 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
神経学的疾患または障害を処置するためのvmat2阻害剤
|
KR20210048600A
(ko)
|
2015-08-17 |
2021-05-03 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
US11103259B2
(en)
|
2015-09-18 |
2021-08-31 |
Vaxxas Pty Limited |
Microprojection arrays with microprojections having large surface area profiles
|
WO2017059385A1
(en)
|
2015-09-30 |
2017-04-06 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
EA201890852A1
(ru)
|
2015-10-30 |
2018-10-31 |
Нейрокрин Байосайенсиз, Инк. |
Соли валбеназина и их полиморфы
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
EP3394057B1
(de)
|
2015-12-23 |
2022-03-30 |
Neurocrine Biosciences, Inc. |
Synthetisches verfahren zur herstellung von (s)-(2r, 3r, 11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]llsochinolin-2-yl-2-amino-3-methylbutanoat-di(4-methylbenzenesulfonat)
|
RU2018127752A
(ru)
|
2015-12-31 |
2020-01-31 |
Конатус Фармасьютикалз Инк. |
Способы применения ингибиторов каспаз при лечении заболеваний печени
|
HUE051231T2
(hu)
|
2016-01-08 |
2021-03-01 |
Celgene Corp |
Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
|
CN108712904B
(zh)
|
2016-01-08 |
2022-08-02 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
|
EP3399980A4
(de)
|
2016-01-08 |
2019-09-04 |
Celgene Corporation |
Verfahren zur behandlung von krebs und verwendung von biomarkern als prädiktor klinischer empfindlichkeit gegenüber therapien
|
WO2017123634A1
(en)
|
2016-01-11 |
2017-07-20 |
Synergy Pharmaceuticals, Inc. |
Formulations and methods for treating ulcerative colitis
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017180589A1
(en)
|
2016-04-11 |
2017-10-19 |
Auspex Pharmaceuticals, Inc. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
ES2912921T3
(es)
|
2016-04-29 |
2022-05-30 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA3036195A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
EP3515414B1
(de)
|
2016-09-19 |
2022-11-30 |
MEI Pharma, Inc. |
Kombinationstherapie
|
BR112019009000A2
(pt)
|
2016-11-03 |
2019-07-16 |
Kura Oncology Inc |
método para tratar um carcinoma refratário, método de tratamento de scchn, método de tratamento de carcinoma de células escamosas, método de tratamento para scc
|
WO2018089427A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
US10799503B2
(en)
|
2016-12-01 |
2020-10-13 |
Ignyta, Inc. |
Methods for the treatment of cancer
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
WO2018140096A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
BR112019017375A2
(pt)
|
2017-02-21 |
2020-03-31 |
Kura Oncology, Inc. |
Método para o tratamento de um câncer que expressa cxcl12 e de linfoma angioimunoblástico de células t (aitl) em um indivíduo
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
WO2018175324A1
(en)
|
2017-03-20 |
2018-09-27 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
CN110914276A
(zh)
|
2017-03-29 |
2020-03-24 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
DK3606760T3
(da)
|
2017-03-31 |
2023-11-06 |
Vaxxas Pty Ltd |
Indretning og fremgangsmåde til belægning af overflader
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
MA49140A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
|
WO2018213810A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
MX2019014272A
(es)
|
2017-06-01 |
2020-12-11 |
Xoc Pharmaceuticals Inc |
Compuestos policiclicos y usos de los mismos.
|
US11175128B2
(en)
|
2017-06-13 |
2021-11-16 |
Vaxxas Pty Limited |
Quality control of substrate coatings
|
EP3661587A4
(de)
|
2017-08-04 |
2021-06-09 |
Vaxxas Pty Limited |
Kompakter hoher mechanischer energiespeicher und aktuator mit geringer auslösekraft für die abgabe von mikroprojektions-array-patches (map)
|
EP3664804A4
(de)
|
2017-08-07 |
2021-04-14 |
Kura Oncology, Inc. |
Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
IL273300B1
(en)
|
2017-09-21 |
2024-02-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3077149A1
(en)
|
2017-10-10 |
2019-04-18 |
Neurocrine Biosciences, Inc. |
Methods for the administration of (s)-2-amino-3-methyl-butyric acid (2r,3r,11br)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2yl ester and salts thereof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス, エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
TW202011963A
(zh)
|
2018-06-14 |
2020-04-01 |
美商紐羅克里生物科學有限公司 |
Vmat2抑制劑化合物、組合物及其相關方法
|
WO2020006341A1
(en)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
TW202031259A
(zh)
|
2018-11-01 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US11572344B2
(en)
|
2018-11-20 |
2023-02-07 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
AU2019384064A1
(en)
|
2018-11-20 |
2021-06-10 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
CN113473986A
(zh)
|
2018-11-20 |
2021-10-01 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
WO2020106303A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
EP3897638A1
(de)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Therapien für plattenepithelkarzinome
|
EP3921038A1
(de)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
KR20220004963A
(ko)
|
2019-03-07 |
2022-01-12 |
코나터스 파마슈티칼스, 인크. |
카스파제 억제제 및 이의 사용 방법
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
TW202043487A
(zh)
|
2019-03-29 |
2020-12-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療鱗狀細胞癌之方法
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
WO2021007474A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
EP4003314A4
(de)
|
2019-07-26 |
2023-09-20 |
Espervita Therapeutics, Inc. |
Funktionalisierte langkettige kohlenwasserstoffmono- und -dicarbonsäuren zur vorbeugung oder behandlung von krankheiten
|
US11788091B2
(en)
|
2019-08-21 |
2023-10-17 |
University Of Virginia Patent Foundation |
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CN115103835A
(zh)
|
2019-09-16 |
2022-09-23 |
戴斯阿尔法公司 |
Il-17a调节剂及其用途
|
EP4034236A1
(de)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Verbindungen zur behandlung von lebererkrankungen
|
KR20220091488A
(ko)
|
2019-10-01 |
2022-06-30 |
몰레큘러 스킨 테라퓨틱스, 인코포레이티드 |
Klk5/7 이중 억제제로서의 벤족사지논 화합물
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
BR112023002659A2
(pt)
|
2020-08-14 |
2023-05-02 |
Siteone Therapeutics Inc |
Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor
|
EP4284377A1
(de)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Verfahren zur behandlung von fibrotischen erkrankungen
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
CA3211505A1
(en)
|
2021-03-10 |
2022-09-15 |
Lalit Kumar Sharma |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
EP4326721A1
(de)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
WO2023102378A1
(en)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
TW202400593A
(zh)
|
2022-03-28 |
2024-01-01 |
美商艾索司特瑞克斯公司 |
Myst家族離胺酸乙醯轉移酶之抑制劑
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|